No improvement seen in representation of Black patients after implementation of a 2015 FDA action plan to improve diversity

Moderate associations seen with anxiety disorder, schizophrenia, bipolar disorder, and depressive disorder, but not substance use disorder

Furthermore, significant changes seen for anxiety, depression, and well-being after therapy dog intervention

Participants who screened positive for depression had worse DED symptoms and composite DED sign score

Additional benefits include reductions in opioid dosing, emotional distress, and opioid craving

10- and 30-year CV risk significantly higher in patients with bipolar disorder, schizophrenia, schizoaffective disorder

Women, including those with mental illness, had a lower risk for self-harm during pregnancy; adolescents had highest risk for self-harm in pregnancy

Risk increased for developing a mental health issue, self-harm, and psychiatric hospitalization after a concussion

No indirect associations seen for symptoms of depression and anxiety with migraine, nonmigraine frequent headache

Reduction seen in rate of change in modifiable cardiovascular risk, but most changes in individual modifiable risk factors were not significant